Composition:
The production of Bromelami Retard® starts from an inert core, which is coated with several layers of bromelain and subsequently covered with acid-fast polymers. The final filming helps to significantly reduce the typical and intense aroma of bromelain, which can be unpleasant or difficult to use in some formulations. The final titration is between 800 and 900 GDU/g.
Dosage: 250-500mg once a day.

Description

Bromelami retard® is a microencapsulated and gastro-resistant bromelain, developed by amitahcand obtained through patented technology*.
* MINIACTIVES Technology, patented by IPS Srl

DELIVERY FORM Capsules, Tablets
THERAPEUTICAL AREA
- Gastrointestinal Wellness
APPLICATION AREA
- Absorbition
AVAILABLE IN
- Iberia
- Italy
- Poland

Bromelami Retard®

Additional info

Additional info

COMPOSITION	The production of Bromelami Retard® starts from an inert core, which is coated with several layers of bromelain and subsequently covered with acid-fast polymers. The final filming helps to significantly reduce the typical and intense aroma of bromelain, which can be unpleasant or difficult to use in some formulations. The final titration is between 800 and 900 GDU/g.
AVAILABE IN	Italy, Poland, Iberia
FORMULATION & DOSAGE	250-500mg once a day.
DELIVERY FORMS	Capsules Tablets

SUBSCRIBE OUR NEWSLETTER

Head Office

Via Como 45-47, 20033 Solaro (MI) - Italy

Phone: +39 02 96798808

Email: [email protected]